『徳島大学 教育・研究者情報データベース (EDB)』---[学外] /
ID: Pass:

登録内容 (EID=389590)

EID=389590EID:389590, Map:0, LastModified:2022年8月23日(火) 19:36:09, Operator:[大家 隆弘], Avail:TRUE, Censor:承認済, Owner:[生島 仁史], Read:継承, Write:継承, Delete:継承.
○種別 (必須): □学術論文 (審査論文) [継承]
○言語 (必須): □英語 [継承]
○招待 (推奨):
○審査 (推奨): □Peer Review [継承]
○カテゴリ (推奨): □研究 [継承]
○共著種別 (推奨): □国内共著 (徳島大学内研究者と国内(学外)研究者との共同研究 (国外研究者を含まない)) [継承]
○学究種別 (推奨):
○組織 (推奨):
○著者 (必須): 1. (英) Murakami Naoya (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
2. (英) Watanabe Miho (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
3. (英) Uno Takashi (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
4. (英) Sekii Shuhei (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
5. (英) Tsujino Kayoko (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
6. (英) Kasamatsu Takahiro (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
7. (英) Machitori Yumiko (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
8. (英) Aoshika Tomomi (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
9. (英) Kato Shingo (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
10. (英) Hirowatari Hisako (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
11. (英) Kaneyasu Yuko (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
12. (英) Nakagawa Tomio (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
13.生島 仁史 ([徳島大学.大学院医歯薬学研究部.保健学域.保健科学部門.放射線科学系.放射線治療学])
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
14. (英) Ando Ken (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
15. (英) Murata Masumi (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
16. (英) Yoshida Ken (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
17. (英) Yoshioka Hiroko (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
18. (英) Murata Kazutoshi (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
19. (英) Ohno Tatsuya (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
20. (英) Okonogi Noriyuki (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
21. (英) Saito Anneyuko (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
22. (英) Ichikawa Mayumi (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
23. (英) Okuda Takahito (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
24. (英) Tsuchida Keisuke (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
25. (英) Sakurai Hideyuki (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
26. (英) Yoshimura Ryouichi (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
27. (英) Yoshioka Yasuo (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
28. (英) Yorozu Atsunoti (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
29. (英) Okamoto Hiroyuki (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
30. (英) Inaba KOji (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
31. (英) Kato Tomoyasu (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
32. (英) Igaki Hiroshi (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
33. (英) Itami Jun (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
○題名 (必須): □(英) Large volume was associated with increased risk of acute non-hematologic adverse events in the hybrid of intracavitary and interstitial brachytherapy for locally advanced uterine cervical cancer: preliminary results of prospective phase I/II clinical trial  (日)    [継承]
○副題 (任意):
○要約 (任意): □(英) This is the preliminary results of a multi-center prospective clinical trial evaluating the feasibility of the hybrid of intracavitary and interstitial brachytherapy for locally advanced cervical cancer. Patients with FIGO stage IB2, IIA2, IIB, IIIA, IIIB and IVA uterine cervical cancer pretreatment width of which was ≥5 cm measured by MRI were eligible. Protocol therapy consisted of 30-30.6 Gy in 15-17 fractions of whole pelvic radiotherapy concurrent with weekly CDDP, followed by 24 Gy in 4 fractions of hybrid of intracavitary and interstitial and pelvic radiotherapy with central shield up to 50-50.4 Gy in 25-28 fractions. The primary endpoint of phase I part was that the rate of grade ≥ 3 acute non-hematologic adverse events related to hybrid of intracavitary and interstitial would be <10%. Between October 2015 and October 2019, 74 patients underwent primary registration, with 52 patients eventually proceeding to the secondary registration. The median pretreatment tumor width was 5.7 cm, and FIGO Stages were IB2 10, IIA2 2, IIB 20 and IIIB 20, respectively. The median high-risk clinical target volume D90 was 72.0 Gy (54.8-86.6 Gy, EQD2), rectum D2cc was 53.7 Gy (29.3-80.3 Gy) and bladder D2cc was 69.8 Gy (38.9-84.8 Gy). The rate of grade ≥ 3 non-hematologic adverse events related to hybrid of intracavitary and interstitial was 1.9% (1/52), and 17.3% (9/52) of patients experienced non-hematologic adverse events related to hybrid of intracavitary and interstitial of any grade. In multivariate analysis, high-risk clinical target volume ≥ 35 ml was associated with an increased risk of any grade of acute non-hematologic adverse events related to hybrid of intracavitary and interstitial (P = 0.036). The feasibility and reproducibility of hybrid of intracavitary and interstitial were demonstrated from a multi-center prospective clinical trial.  (日)    [継承]
○キーワード (推奨): 1. (英) Brachytherapy (日) (読) [継承]
2. (英) Female (日) (読) [継承]
3. (英) Humans (日) (読) [継承]
4. (英) Prospective Studies (日) (読) [継承]
5. (英) Radiotherapy Dosage (日) (読) [継承]
6. (英) Reproducibility of Results (日) (読) [継承]
7. (英) Uterine Cervical Neoplasms (日) (読) [継承]
○発行所 (推奨):
○誌名 (必須): □Japanese Journal of Clinical Oncology (Foundation of Clinical Oncology/Gan Kenkyu Shinkokai)
(pISSN: 0368-2811, eISSN: 1465-3621)

○ISSN (任意): □1465-3621
ISSN: 0368-2811 (pISSN: 0368-2811, eISSN: 1465-3621)
Title: Japanese journal of clinical oncology
Title(ISO): Jpn J Clin Oncol
Supplier: Oxford University Press
Publisher: Oxford University Press
 (NLM Catalog)   (医中誌Web)   (Scopus)   (CrossRef)  (Scopus information is found. [need login])
[継承]
[継承]
○巻 (必須): □52 [継承]
○号 (必須): □8 [継承]
○頁 (必須): □851 860 [継承]
○都市 (任意):
○年月日 (必須): □西暦 2022年 4月 25日 (令和 4年 4月 25日) [継承]
○URL (任意):
○DOI (任意): □10.1093/jjco/hyac072    (→Scopusで検索) [継承]
○PMID (任意): □35470390    (→Scopusで検索) [継承]
○CRID (任意):
○Scopus (任意):
○researchmap (任意):
○評価値 (任意):
○被引用数 (任意):
○指導教員 (推奨):
○備考 (任意): 1.(英) Article.ELocationID: 10.1093/jjco/hyac072  (日)    [継承]
2.(英) Article.PublicationTypeList.PublicationType: Clinical Trial, Phase I  (日)    [継承]
3.(英) Article.PublicationTypeList.PublicationType: Clinical Trial, Phase II  (日)    [継承]
4.(英) Article.PublicationTypeList.PublicationType: Journal Article  (日)    [継承]
5.(英) Article.PublicationTypeList.PublicationType: Multicenter Study  (日)    [継承]
6.(英) KeywordList.Keyword: combined intracavitary/interstitial brachytherapy  (日)    [継承]
7.(英) KeywordList.Keyword: hybrid of intracavitary and interstitial brachytherapy  (日)    [継承]
8.(英) KeywordList.Keyword: image-guided adaptive brachytherapy  (日)    [継承]
9.(英) KeywordList.Keyword: prospective clinical trial  (日)    [継承]
10.(英) KeywordList.Keyword: uterine cervical cancer  (日)    [継承]

標準的な表示

和文冊子 ● Naoya Murakami, Miho Watanabe, Takashi Uno, Shuhei Sekii, Kayoko Tsujino, Takahiro Kasamatsu, Yumiko Machitori, Tomomi Aoshika, Shingo Kato, Hisako Hirowatari, Yuko Kaneyasu, Tomio Nakagawa, Hitoshi Ikushima, Ken Ando, Masumi Murata, Ken Yoshida, Hiroko Yoshioka, Kazutoshi Murata, Tatsuya Ohno, Noriyuki Okonogi, Anneyuko Saito, Mayumi Ichikawa, Takahito Okuda, Keisuke Tsuchida, Hideyuki Sakurai, Ryouichi Yoshimura, Yasuo Yoshioka, Atsunoti Yorozu, Hiroyuki Okamoto, KOji Inaba, Tomoyasu Kato, Hiroshi Igaki and Jun Itami : Large volume was associated with increased risk of acute non-hematologic adverse events in the hybrid of intracavitary and interstitial brachytherapy for locally advanced uterine cervical cancer: preliminary results of prospective phase I/II clinical trial, Japanese Journal of Clinical Oncology, 52, 8, 851-860, 2022.
欧文冊子 ● Naoya Murakami, Miho Watanabe, Takashi Uno, Shuhei Sekii, Kayoko Tsujino, Takahiro Kasamatsu, Yumiko Machitori, Tomomi Aoshika, Shingo Kato, Hisako Hirowatari, Yuko Kaneyasu, Tomio Nakagawa, Hitoshi Ikushima, Ken Ando, Masumi Murata, Ken Yoshida, Hiroko Yoshioka, Kazutoshi Murata, Tatsuya Ohno, Noriyuki Okonogi, Anneyuko Saito, Mayumi Ichikawa, Takahito Okuda, Keisuke Tsuchida, Hideyuki Sakurai, Ryouichi Yoshimura, Yasuo Yoshioka, Atsunoti Yorozu, Hiroyuki Okamoto, KOji Inaba, Tomoyasu Kato, Hiroshi Igaki and Jun Itami : Large volume was associated with increased risk of acute non-hematologic adverse events in the hybrid of intracavitary and interstitial brachytherapy for locally advanced uterine cervical cancer: preliminary results of prospective phase I/II clinical trial, Japanese Journal of Clinical Oncology, 52, 8, 851-860, 2022.

関連情報

Number of session users = 5, LA = 2.79, Max(EID) = 468004, Max(EOID) = 1244016.